<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1704245170
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TEVETEN PLUS 600-12.5MG FILM COATED TAB.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HYDROCHLOROTHIAZIDE,EPROSARTAN MESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        12.5,600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        76.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Mylan Laboratories SAS " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Mylan Laboratories SAS 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbott Laboratories GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Teveten Plus is indicated for the treatment of essential hypertension.</p><p>&nbsp;</p><p>Teveten Plus contains two active ingredients: eprosartan and hydrochlorothiazide.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>eprosartan </strong>belongs to a group of medicines called &ldquo;angiotensin II receptor antagonists&rdquo;. It blocks the action of a substance in your body called &lsquo;angiotensin II&rsquo;. This substance causes your blood vessels to narrow. This makes it more difficult for the blood to flow through the vessels and so your blood pressure increases. By blocking this substance, the vessels relax and your blood pressure decreases.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>hydrochlorothiazide</strong><strong> </strong>belongs to a group of medicines called &ldquo;thiazide diuretics&rdquo;. It increases how often and how much urine you pass. This decreases your blood pressure</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to eprosartan, hydrochlorothiazide or any of the other ingredients of this medicine (listed in Section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to a group of medicines called &lsquo;sulfonamides&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are more than 3 months pregnant (it is also better to avoid Teveten Plus in early pregnancy &ndash; see pregnancy section).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have <strong>severe </strong>liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have <strong>severe </strong>kidney disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severe problems with the blood flow in your kidneys</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have high calcium, low potassium or low sodium levels. These are all things that can be measured in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a problem with your gall bladder or bile duct ( gallstones)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have gout or other signs of a raised &ldquo;uric acid&rdquo; level in your blood (hyperuricaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren</p><p>Do not take Teveten Plus if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p>Warnings and precautions</p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or pharmacist before taking Teveten Plus if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any other liver problem</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had a kidney transplant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any other kidney problems. Your doctor will check how well your kidneys are working before you start your treatment and at intervals during your treatment. Your doctor will check the potassium, creatinine and &lsquo;uric acid&rsquo; levels in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a heart problem such as coronary heart disease, heart failure, a narrowing of your blood vessels or heart valves, or a problem with your heart muscle</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a condition called &lsquo;Systemic Lupus Eryhthematosus&rsquo; (SLE)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have diabetes. Your doctor may need to alter the dose of your diabetic medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you produce too much of a hormone called &ldquo;aldosterone&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a history of any allergies</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are on a low-salt diet, taking &lsquo;water tablets&rsquo; (diuretics) or are being sick or have diarrhoea. This is because they may cause your blood volume or the sodium level in your blood to decrease. These should be corrected before starting treatment with Teveten Plus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking any of the following medicines used to treat high blood pressure:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading &ldquo;Do not take Teveten Plus&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you think you are (or might become) pregnant. Teveten Plus is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage - see pregnancy section.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Teveten Plus.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have had skin cancer or if you develop an unexpected skin lesion during the treatment. Treatment with hydrochlorothiazide, particularly long term use with high doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer). Protect your skin from sun exposure and UV rays while taking Teveten Plus</p><p>&nbsp;</p><p>Tell your doctor if you have changes in your vision or pain in one or both of your eyes while taking product. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or you are developing glaucoma, increased pressure in your eye(s). You should discontinue product treatment and seek medical attention.</p><p>&nbsp;</p><p>Treatment with hydrochlorothiazide may cause electrolyte imbalance in your body. Your doctor may check the electrolytes in your blood regularly.</p><p>&nbsp;</p><p>Operations and tests</p><p>Talk to your doctor or pharmacist before taking this medicine if you are due to have the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an operation or surgery</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an anti-doping test. The hydrochlorothiazide in this medicine may lead to a positive result</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any other blood tests.</p><p>Other medicines and Teveten Plus</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, including herbal medicines. This is because Teveten Plus can affect the way some other medicines work. Also some other medicines can affect the way Teveten Plus works.</p><p>&nbsp;</p><p>In particular, tell your doctor or pharmacist if you are taking the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium &ndash; for mood problems. Your doctor must monitor the lithium level in your blood because Teveten Plus may increase the level</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for diabetes such as metformin or insulin. Your doctor may need to alter the dose of your diabetic medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which can cause potassium loss. These include &lsquo;water tablets&rsquo;, &lsquo;laxatives&rsquo;, &lsquo;corticosteroids&rsquo;, amphotericin (an anti-fungal medicine), carbenoxolone (treatment of mouth ulcers) and a hormone produced by the pituitary gland called &lsquo;ACTH&rsquo;. Teveten Plus may increase the risk of low blood potassium levels when taken with these medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which can reduce the amount of sodium in your blood. These include medicines to treat depression, psychosis and epilepsy. Teveten Plus may increase the risk of low blood sodium levels when taken with these medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-steroidal anti-inflammatory drugs (NSAIDs) e.g. ibuprofen, naproxen, diclofenac, indometacin, acetylsalicylic acid, celecoxib or etoricoxib &ndash; medicines to relieve pain and inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digitalis glycosides such as digoxin used for heart failure or a fast and irregular heart beat. Teveten Plus may increase the risk for irregular heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; beta-blockers and diazoxide. When taken with Teveten Plus the sugar level in your blood may increase</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat cancer such as &lsquo;methotrexate&rsquo; and &lsquo;cyclophosphamide&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that tighten your blood vessels or stimulate your heart, such as noradrenaline</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which relax your muscles such as &lsquo;baclofen&rsquo; and &lsquo;tubocurarin&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaesthetics</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amantadine used to treat Parkinson&rsquo;s disease or viral diseases. Teveten Plus may increase the risk of side effects caused by amantadine.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Teveten Plus.</p><p>Your doctor may need to change your dose and/or to take other precautions:</p><p>If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Teveten Plus&rdquo; and &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>The following medicines may decrease the effect of Teveten Plus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which decrease fat in your blood such as &lsquo;colestipol&rsquo; and &lsquo;cholestyramine&rsquo;.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Teveten Plus.</p><p>&nbsp;</p><p>The following medicines may increase the effect of Teveten Plus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep-inducing medicines such as &lsquo;sedatives&rsquo; and &lsquo;narcotics&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for Parkinson&rsquo;s disease such as &lsquo;biperiden&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that lower your blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lsquo;amifostine&rsquo; a medicine which protects cells from chemotherapy</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Teveten Plus.</p><p>If you are taking any of the following medicines your doctor may carry out blood tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines containing potassium or potassium sparing medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that increase potassium levels such as &lsquo;heparin&rsquo; and &lsquo;ACE inhibitors&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for gout such as &lsquo;probenecid&rsquo;, &lsquo;sulfinpyrazone&rsquo; and &lsquo;allopurinol&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for diabetes such as &lsquo;metformin&rsquo; and &lsquo;insulin&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to control the rhythm of your heart such as quinidine, disopyramide, amiodarone and sotalol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antibiotics such as &lsquo;tetracyclines&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antipsychotic medicines such as thioridazine, chlorpromazine and levopromazine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; calcium salts or Vitamin D</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; steroids.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before taking Teveten Plus. Depending on the outcome of your blood tests, your doctor may decide to change your treatment with these medicines or Teveten Plus.</p><p>&nbsp;</p><p>Teveten Plus with food, drink and alcohol</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take the tablets with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drinking alcohol while taking Teveten Plus can reduce your blood pressure and you may feel tired or dizzy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Speak to your doctor before taking Teveten Plus if you are on a low salt diet. Not having enough salt may cause your blood volume or the sodium level in your blood to get lower.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p><strong>&nbsp;</strong></p><p>If you are pregnant or breastfeeding, or if you suspect you are pregnant or intend to become pregnant, consult your doctor and pharmacist before taking this medicine.</p><p>Pregnancy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Teveten Plus before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Teveten Plus.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Teveten Plus is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant. It may cause serious harm to your baby if used after the third month of pregnancy.</p><p>&nbsp;</p><p>Breast-feeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you are breast-feeding or about to start breast-feeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Teveten Plus is not recommended for mothers who are breast-feeding. Your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Teveten Plus is unlikely to affect your ability to drive or use tools and machines. However, you may feel sleepy or dizzy while taking Teveten Plus. If this happens do not drive or use any tools or machines and talk to your doctor.</p><p>&nbsp;</p><p>Teveten Plus contains lactose</p><p>Teveten Plus contains lactose (a type of sugar). If you have been told by your doctor that you cannot tolerate or digest some sugars, talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Taking this medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take this medicine by mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet whole with plenty of fluid such as a glass of water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not crush or chew the tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the tablets in the morning at around the same time each day.</p><p>&nbsp;</p><p>How much to take Adults</p><p>The usual dose is one tablet a day.</p><p>&nbsp;</p><p>Use in children and adolescents</p><p>Teveten Plus should not be given to children and adolescents under 18 years.</p><p>&nbsp;</p><p>If you take more Teveten Plus than you should</p><p>If you take more Teveten Plus than you should or someone accidently takes some, talk to a doctor or go to a hospital straight away.</p><p>Take the medicine pack with you. The following effects can happen:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling light-headed and dizzy due to a fall in your blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling thirsty (dehydration).</p><p>&nbsp;</p><p>If you forget to take Teveten Plus</p><p>If you forget a dose, take it as soon as you remember it.</p><p>If you forget to take a dose and it is nearly time for your next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop taking Teveten Plus</p><p>Do not stop taking Teveten Plus without talking to your doctor first.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>&nbsp;</p><p>Allergic reactions</p><p>If you have an allergic reaction, stop taking Teveten Plus and see a doctor straight away. The signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reactions such as a rash or hives with swelling (urticaria), (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your face, swelling of skin and mucous membrane (angioedema), (may affect up to 1 in 100 people)</p><p><strong>Other possible side effects of Teveten Plus include: Very common </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pins and needles, nerve pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick, being sick or diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak (asthenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stuffy nose (rhinitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure, including low blood pressure when standing up. You may feel light-headed or dizzy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood tests such as increased blood level of glucose (hyperglycaemia)</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling depressed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling anxious or nervous</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sexual dysfunction and/or change of sexual desire</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood tests such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of uric acid (gout)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in fat (cholesterol,)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased potassium, sodium and chloride levels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of white blood cells</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water in the lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas</p><p>&nbsp;</p><p><strong>Very rare </strong>(may affect less than 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haemolytic anaemia</p><p>&nbsp;</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>Lack of appetite, jaundice, Decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma), feeling restless, changes in blood count: decrease granulocytes and platelets, disturbance of red blood cell formation; decreased level magnesium in the blood, increased level of calcium and triglycerides in the blood, renal disorders, inflammation of the kidney, acute renal failure, inflammation of blood vessel wall, formation of skin bubbles including dead skin cells (toxic epidermal necrolysis), rash/skin lesions usually on sun-exposed areas due to an autoimmune disease (cutaneous lupus erythematosus), systemic lupus erythematosus, severe allergic reactions (anaphylactic reactions), increased sensitivity to (sun)light (photosensitivity), skin and lip cancer (non-melanoma skin cancer).</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>To report any side effect(s):</strong></p><p>-National Pharmacovigilance Center (NPC)</p><p><strong>o </strong>Fax: +966-11-205-7662</p><p><strong>o </strong>SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Store below 30&deg;C.</p><p>Store in the original packaging.</p><p>Shelf Life: 3 years</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; information What Teveten Plus contains</p><p>The active substances are 600 mg eprosartan (as mesylate) and 12.5 mg hydrochlorothiazide per tablet. The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet core: lactose monohydrate, microcrystalline cellulose, pregelatinized starch (from maize), crospovidone, magnesium stearate, purified water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Film coat: polyvinyl alcohol, talc, titanium dioxide (E171), macrogol 3350, iron oxide yellow (E172), iron oxide black (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Teveten Plus looks like and contents of the pack

Butterscotch-coloured, capsule-shaped film-coated tablets. They are marked 5147 on one side of the tablet.
Teveten Plus is provided in blisters containing 7, 14, 28, 56, and 98 tablets. 
The blister packs are made of opaque PVC/PCTFE/Alu. 
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer</p><p><strong>Marketing</strong><strong> </strong><strong>Authorisation</strong><strong> </strong><strong>Holder</strong></p><p>Abbott laboratories GmbH,</p><p>Hannover Germany</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Mylan Laboratoires SAS</p><p>01400 Ch&acirc;tillon-sur-Chalaronne, France</p><p>&nbsp;</p><p><strong>Packaged </strong><strong>by: </strong></p><p>AJA Pharmaceutical Industries Company Ltd. (AJA Pharma)</p><p>Hail 55414, Hail Industry City MODON</p><p>Kingdom of Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in November 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُستخدم تيفيتين بلس لمعالجة فرط ضغط الدم الأساسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي تيفيتين بلس على المكونين الفعالين: إبروسارتان وهيدروكلوروثيازيد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إبروسارتان</strong> ينتمي إلى مجموعة من الأدوية تسمى &quot;مثبطات مستقبلات أنجيوتنسين 2&quot;. وهو يُثبِّط عمل مادة في جسمك تسمى &quot;أنجيوتنسين &ndash;2&quot; وتسبب هذه المادة ضيق الأوعية الدموية. وهذا يعيق تدفق الدم خلال الأوعية الدموية مما يؤدي إلى ارتفاع ضغط الدم. وعن طريق إحصار هذه المادة، تسترخي الأوعية الدموية وينحفض ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>هيدروكلوروثيازيد</strong> ينتمي إلى مجموعة من الأدوية تسمى &quot;مدرات البول الثيازيدية&quot;. وهو يزيد عدد مرات تبولك وكمية البول التي تتبولها. وهذا يقلل من ضغط الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا</strong><strong> </strong><strong>تستعمل</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط الحساسية تجاه إبروسارتان، أو هيدروكلوروثيازيد أو تجاه أي من المكونات الأخرى لهذا الدواء )المدرجة في القسم 6 (.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط الحساسية تجاه مجموعة من الأدوية التي تسمى &quot;سلفوناميدات&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً لأكثر من 3 أشهر )من الأفضل أيضاً عدم تناول تيفيتين بلس في بداية الحمل - انظر أيضاً قسم &quot;الحمل&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض <strong>حاد</strong> في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض <strong>حاد</strong> في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل حادة في تدفق الدم في الكليتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع مستويات الكالسيوم، وانخفاض مستويات البوتاسيوم أو الصوديوم في الدم .وهذه جميعاً يمكن قياسها في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة في المرارة أو القناة الصفراوية )الحصوات الصفراوية(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من النقرس أو علامات أخرى تشير إلى زيادة مستوى &quot;حمض اليوريك&quot; في دمك )فرط حمض يوريك الدم(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بداء السكري أو اضطراب وظائف الكلى وكنت تعالج بالأدوية التي تعمل على خفض ضغط الدم والتي تحتوي على أليسكيرين.يجب عدم تناول تيفيتين بلس إذا كان أيٌّ مما سبق ينطبق عليك. إذا لم تكن متأكداً، فتحدث مع طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات</strong><strong> </strong><strong>والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو إلى الصيدلي قبل تناول تيفيتين بلس في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل أخرى في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت لعملية زرع الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل أخرى في الكلى، فسيقوم طبيبك بتقييم وظائف الكلى لديك قبل بدء العلاج وعلى فترات أثناء العلاج. وسيقوم طبيبك بفحص مستويات البوتاسيوم والكرياتينين و&quot;حمض اليوريك&quot; في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل في القلب مثل أمراض القلب التاجية، وفشل القلب، وتضييق الأوعية الدموية أو صمامات القلب، أو مشكلة في عضلة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلب.إذا كانت لديك حالة تسمى &quot;الذئبة الحمامية الجهازية(SLE) &quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض السكري. فقد يحتاج طبيبك إلى تغيير جرعة أدوية السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط إفراز هرمون يسمى &quot;الألدوستيرون&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ منالإصابة بأي نوع من أنواع الحساسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت على نظام غذائي منخفض الملح، أو تتناول أقراص المياه )مدرات البول) أو تعاني من الغثيان أو الإسهال؛ لأن ذلك قد يتسبب في انخفاض حجم الدم أو مستوى الصوديوم في الدم.</p><p dir="RTL">وينبغي تصحيح هذه المستويات قبل بدء العلاج باستخدام تيفيتين بلس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أيّاً من الأدوية التالية لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الإنزيم المحول للأنجيوتنسين (على سبيل المثال إنالابريل، ليسينوبريل، راميبريل)، خاصة إذا كان لديك مشاكل في الكلى</p><p dir="RTL">ذات صلة بالسكري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين</p><p dir="RTL">قد يقوم طبيبك بإجراء فحص منتظم على وظائف الكلى وضغط الدم وكمية الشوارد الكهربائية (مثل البوتاسيوم) في الدم. انظر أيضاً المعلومات الواردة في قسم &quot;لا تأخذ هذا الدواء&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو تعتقدين أنكِ حامل أو تريدين أن تصبحين حاملاً. لا ينصح بتناول هذا الدواء في بداية الحمل. إذا كنت حاملاً لأكثر من 3 أشهر، فلا ينبغي تناول الدواء، لأنه قد يكون له آثار ضارة وخطيرة على الطفل إذا ما تم تناوله في هذه المرحلة - انظر قسم &quot;الحمل&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا کان أيٌّ من الحالات المذکورة أعلاه تنطبق عليك (أو إذا لم تكن متأكدًا)، فتحدث إلى طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بسرطان الجلد أو إذا أُصبت بمرض جلدي غير متوقع خلال العلاج. فالعلاج باستخدام هيدروكلوروثيازيد، خاصة على المدى الطويل بجرعات عالية قد يزيد من مخاطر الإصابة ببعض أنواع سرطان الجلد والشفاة (سرطان الجلد غير الميلانينيّ). اهتم بحماية جلدك من التعرض للشمس والأشعة فوق البنفسجية طول مدة تناول تيفيتين بلس</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كانت لديك تغييرات في رؤيتك أو ألم في إحدى أو كلتى عينيك طول مدة تناول هذا المنتج. فهذا يمكن أن يكون علامة على تراكم السائل في الطبقة الوعائية للعين (انصباب المشيميَّة) أو الإصابة بالجلوكوما، وزيادة الضغط في عينك (عينيك). يجب عليك التوقف عن تناول العلاج والتماس العناية الطبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">العلاج بتناول هيدروكلوروثيازيد قد يسبب عدم توازن الشوارد الكهربائية في الجسم. قد يتحقق طبيبك من كمية الشوارد الكهربائية في الدم بانتظام.</p><p dir="RTL"><strong>العمليات</strong><strong> </strong><strong>والاختبارات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول هذا الدواء إذا كان من المقرر أن يُجرى لك أيٌّ ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عملية جراحية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار الكشف عن المنشطات. فقد تؤدي مادة هيدروكلوروثيازيد الموجودة في هذا الدواء إلى نتيجة إيجابية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي اختبارات أخرى في الدم</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخراً أي أدوية أخرى، وهذا يشمل الأدوية التي يتم الحصول عليها دون</p><p dir="RTL">وصفة طبية، بما في ذلك الأدوية العشبية. وذلك لأن تيفيتين بلس يمكن أن يؤثر على طريقة عمل بعض الأدوية الأخرى. ويمكن أن تؤثر بعض</p><p dir="RTL">الأدوية الأخرى كذلك على طريقة عمل تيفيتين بلس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وعلى</strong><strong> </strong><strong>وجه</strong><strong> </strong><strong>الخصوص،</strong><strong> </strong><strong>تأكد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>إخبار</strong><strong> </strong><strong>الطبيب أو الصيدلي</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>أيّاً</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم &ndash; لعلاج المشكلات المرتبطة بالحالة المزاجية. يجب على الطبيب مراقبة مستوى الليثيوم في الدم لأن تيفيتين بلس قد يزيد من مستوى الليثيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مرض السكري مثل ميتفورمين أو الأنسولين. فقد يحتاج طبيبك إلى تغيير جرعة أدوية السكري</p><p dir="RTL">الأدوية التي يمكن أن تسبب فقدان البوتاسيوم. وتشمل هذه الأدوية &quot;أقراص المياه&quot;، &quot;الملينات&quot;، &quot;ستيرويدات القشرية (كورتيكوستيرويدات)&quot;، أمفوتريسين (دواء مضاد للفطريات(، كاربينوكسولون )علاج قرح الفم) والهرمون الذي تنتجه الغدة النخامية المسمى &quot;ACTH&quot;. تيفيتين بلس قد يزيد من خطر انخفاض مستويات البوتاسيوم في الدم عند تناوله مع هذه الأدوية</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تخفض كمية الصوديوم في الدم. وتتضمن هذه الأدوية أدوية علاج الاكتئاب والذهان والصرع. فقد يزيد تيفيتين بلس من مخاطر انخفاض مستويات الصوديوم في الدم عند تناوله مع هذه الأدوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المسكنات غير الستيرويدية التي تعمل كمضادات للالتهابات (NSAID) على سبيل المثال، ايبوبروفين، نابروكسين، ديكلوفيناك، إندوميتاسين، حمض أسيتيل ساليسيليك، سيليكوكسيب أو إتوريكوكسيب - أدوية لتخفيف الألم والالتهاب</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جليكوسيدات القلب مثل ديجوكسين المستخدم لفشل القلب أو ضربات القلب السريعة وغير المنتظمة. تيفيتين بلس قد يزيد من خطر عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا وديازوكسيد. عندما يتم تناولها مع تيفيتين بلس قد تزيد مستوى السكر في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج السرطان مثل &quot;ميثوتريكسيت&quot; و&quot;سيكلوفوسفاميد&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤدي إلى ضيق الأوعية الدموية أو تحفيز القلب، مثل نورادرينالين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعمل على استرخاء عضلاتك مثل &quot;باكلوفين&quot; و&quot;توبوكورارين&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية التخدير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمانتادين الذي يُستخدم لعلاج مرض باركنسون أو الأمراض الفيروسية. تيفيتين بلس قد يزيد من خطر الآثار الجانبية الناجمة عن أمانتادين.إذا كانت أيٌّ من الحالات السابقة تنطبق عليك )أو إذا لم تكن متأكداً(، فتحدث مع طبيبك أو الصيدلي قبل تناول تيفيتين بلس.</p><p dir="RTL">فقد يحتاج طبيبك إلى تغيير جرعتك و/أو توخي احتياطات أخرى:</p><p dir="RTL">إذا كنت تتناول أحد الأدوية المثبطة للإنزيم المُحوِّل للأنجيوتنسين أو أليسكيرين (انظر أيضاً المعلومات الواردة تحت قسم &quot;لا تتناول تيفيتين بلس&quot; وقسم &quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تقلل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>تأثير</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تقلل من نسبة الدهون في دمك مثل &quot;كولستيبول&quot; و&quot;كولسترامين&quot;.</p><p dir="RTL">إذا كانت أيٌّ من الحالات السابقة تنطبق عليك )أو إذا لم تكن متأكداً(، فتحدث مع طبيبك أو الصيدلي قبل تناول تيفيتين بلس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تزيد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>تأثير</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تحفز النوم مثل &quot;المهدئات&quot; و&quot;المخدرات&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أدوية مرض باركنسون مثل &quot;بيبيريدن&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تخفض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;أميفوستين&quot; دواء يحمي الخلايا من العلاج الكيميائي</p><p dir="RTL">إذا كانت أيٌّ من الحالات السابقة تنطبق عليك )أو إذا لم تكن متأكداً(، فتحدث مع طبيبك أو الصيدلي قبل تناول تيفيتين بلس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>أيّاً</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>التالية، فقد</strong><strong> </strong><strong>يقوم</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>بإجراء</strong><strong> </strong><strong>فحوصات</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تحتوي على البوتاسيوم أو الأدوية الموفرة للبوتاسيوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تزيد من مستويات البوتاسيوم مثل &quot;هيبارين&quot; و&quot;مثبطات الإنزيم المُحوِّل للأنجيوتنسين&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية النقرس مثل &quot;بروبينيسيد&quot;، &quot;سولفينبيرازون&quot;، &quot;ألوبيورينول&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مرض السكري مثل &quot;ميتفورمين&quot; و&quot;أنسولين&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية السيطرة على انتظام معدل ضربات قلبك مثل كينيدين، ديسوبيراميد، أميودارون، سوتالول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية مثل &quot;تتراسيكلين&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المضادة للذهان مثل ثيوريدازين، كلوربرومازين، ليفوبرومازين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أملاح الكالسيوم أو فيتامين )د(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستيرويدات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول تيفيتين بلس. اعتماداً على نتائج اختبارات الدم الخاصة بك، قد يقرر الطبيب تغيير العلاج الخاص</p><p dir="RTL">بك مع هذه الأدوية أو تيفيتين بلس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطعام</strong><strong> </strong><strong>والشراب</strong><strong> </strong><strong>والكحوليات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول أقراص تيفيتين بلس مع الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرب الكحول مع تناول تيفيتين بلس يمكن أن يقلل من ضغط الدم وقد تشعر بالتعب أو بالدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتبع نظاماً غذائياً منخفض الملح،فأخبر طبيبك قبل البدء في تناول تيفيتين بلس. إذا لم تحصل على كمية كافية من الملح، فقد يقل حجم الدم أو مستوى الصوديوم في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة، أو تعتقدين أنك قد تكونين حاملاً أو تخططين للحمل، فاطلبي من طبيبكِ أو الصيدلي المشورة قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري طبيبكِ إذا كنتِ تعتقدين أنك حامل أو تريدين أن تصبحين حاملاً؛ فعادة ما ينصحك طبيبك بالتوقف عن تناول هذا الدواء قبل الحمل أو بمجرد أن تعرفين أنكِ حامل وسوف ينصحكِ طبيبكِ بتناول دواء آخر بدلاً من تيفيتين بلس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُنصح باستخدام هذا الدواء أثناء المراحل الأولى من الحمل. يجب عدم استخدام الدواء إذا كنت حاملاً لأكثر من 3 أشهر، لأنه يمكن أن يكون له آثار سلبية خطيرة على الطفل إذا تم استخدامه في هذه الفترة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري طبيبكِ إذا كنت ترضعين أو على وشك البدء في الرضاعة الطبيعية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُنصح بهذا الدواء للأمهات المرضعات. يمكن لطبيبكِ اختيار علاج آخر لكِ إذا كنت ترغبين في الرضاعة الطبيعية، خاصة إذا كان طفلك حديث الولادة أو ولد قبل الأوان المحدد لولادته.</p><p dir="RTL">إذا كنت حاملاً أو مرضعة، أو تعتقدين أنك قد تكونين حاملاً أو تخططين للحمل، فاطلبي من طبيبكِ أو الصيدلي المشورة قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">من غير المرجح أن يؤثر تناول تيفيتين بلس على قدرتك على قيادة السيارة أو استخدام الأدوات والآلات. ومع ذلك، قد تشعر بالنعاس أو بالدوار أثناء تناول تيفيتين بلس. إذا حدث هذا، فلا تقم بالقيادة أو تستخدم أي أدوات أو آلات وتحدث إلى طبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس</strong><strong> </strong><strong>على</strong><strong> </strong><strong>اللاكتوز</strong></p><p dir="RTL">تحتوي أقراص تيفيتين بلس على اللاكتوز )نوع من السكريات(. إذا أخبرك طبيبك بعدم قدرتك على تحمل بعض السكريات، فاتصل بطبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدواء متبعاً وصفة الطبيب بدقة، استشر طبيبك أو الصيدلي إن لم تكن متأكداً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول هذا الدواء عن طريق الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع القرص بكامله مع كمية وفيرة من السوائل مثل كوب من الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بسحق الأقراص أو مضغها.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تناول الأقراص في الصباح في نفس الوقت تقريباً كل يوم<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام</strong><strong> </strong><strong>للبالغين</strong></p><p dir="RTL">الجرعة الموصى بها هي قرص واحد يومياً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام</strong><strong> </strong><strong>للأطفال</strong><strong> </strong><strong>والمراهقين</strong></p><p dir="RTL">لا ينبغي استخدام تيفيتن للأطفال والمراهقين الذين تقل أعمارهم عن 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>زائدة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس</strong></p><p dir="RTL">إذا تناولت جرعة زائدة من تيفيتين بلس، أو إذا تناول شخص عن طريق الخطأ بعض الأقراص، فاتصل بطبيبك على الفورأو توجه على الفور إلى أقرب مستشفى.</p><p dir="RTL">تذكر أن تأخذ عبوة الدواء معك. يمكن حدوث الآثار الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار أو الدوخة بسبب حدوث انخفاض في ضغط الدم (انخفاض ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (الغثيان(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعطش )الجفاف(.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس </strong></p><p dir="RTL">إذا نسيت أن تتناول جرعة من الأقراص، فتناولها بمجرد أن تتذكرها، ما لم يكن وقت الجرعة التالية قد اقترب. ولا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس</strong></p><p dir="RTL">اتصل بطبيبك أولاً قبل التوقف عن تناول هذا الدواء.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في آثار جانبية، على الرغم من عدم حدوث ذلك لكل الأشخاص. الآثار الجانبية التالية قد تحدث عند تناول هذا الدواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية</strong></p><p dir="RTL">إذا أُصبت بأحد تفاعلات الحساسية، فتوقف عن تناول تيفيتين بلس ويجب زيارة الطبيب على الفور. قد تشمل العلامات ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية مثل الطفح الجلدي أو الشرى المصحوب بتورم )أرتكاريا(، (قد تصيب ما يصل إلى 1 من كل 10 أشخاص(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه، وتورم في الجلد والغشاء المخاطي )وذمة وعائية(، (قد تصيب ما يصل إلى 1 من كل100 شخص(</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الآثار الجانبية المحتملة الأخرى</strong><strong> </strong><strong>لدواء تيفيتن بلس ما يلي</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة</strong><strong> </strong><strong>جداً (قد</strong><strong> </strong><strong>تصيب</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> </strong><strong>شخص</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> </strong><strong>10 </strong><strong>أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL"><strong>شائعة </strong><strong>)</strong><strong>قد</strong><strong> </strong><strong>تصيب</strong><strong> </strong><strong>ما</strong><strong> </strong><strong>يصل</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>شخص</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> </strong><strong>10 </strong><strong>أشخاص</strong><strong>(</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالوخز، ألم الأعصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء أو الغثيان أو الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الشعور بالضعف (الوهن(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة الجلدية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأنف (التهاب الأنف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم، بما في ذلك انخفاض ضغط الدم عند الوقوف. قد تشعر بالدوخة أو بالدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في اختبارات الدم مثل زيادة مستوى الجلوكوز في الدم )فرط سكر الدم(</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة (قد</strong><strong> </strong><strong>تصيب</strong><strong> </strong><strong>ما</strong><strong> </strong><strong>يصل</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>شخص</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> </strong><strong>100 </strong><strong>شخص</strong><strong>(</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم )الأرق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالقلق أو العصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العجز الجنسي و/ أو تغير الرغبة الجنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات بالعضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحُمّى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار (الدوخة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في اختبارات الدم مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى حمض اليوريك (النقرس(</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الدهون (الكوليسترول(</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البوتاسيوم والصوديوم والكلوريد</p><p>انخفاض عدد خلايا الدم البيضاء</p><p dir="RTL"><strong>نادرة </strong>(قد تصيب ما يصل إلى شخص من كل 1000 شخص(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الماء في الرئتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة</strong><strong> </strong><strong>جداً </strong>)قد تصيب ما يصل إلى شخص من كل 10000 شخص(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم الانحلالي</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير معروفة</strong> (أعراض جانبية أخرى يتعذر تقدير معدل تكرارها من البيانات المتاحة(</p><p dir="RTL">نقص الشهية واليرقان و انخفاض في الرؤية أو ألم في العين بسبب ارتفاع الضغط (علامات محتملة لتراكم السائل في الطبقة الوعائية للعين (انصباب المشيميَّة) أو زرق انسداد الزاوية الحاد)، والشعور بالتململ، وتغيرات في تعداد مكونات الدم: انخفاض الكريات البيضاء المحببة والصفائح الدموية، واضطراب تكوين خلايا الدم الحمراء، وانخفاض مستوى المغنيسيوم في الدم، وزيادة مستوى الكالسيوم والدهون الثلاثية في الدم، واضطرابات بالكلى، والتهاب الكلى والفشل الكلوي الحاد، والتهاب جدار الأوعية الدموية، وتكون فقاعات بالجلد بما في ذلك خلايا الجلد الميتة (تقشر الأنسجة المتموتة البشروية التسممي)، والطفح الجلدي / الآفات الجلدية التي تصيب عادة المناطق المعرضة لأشعة الشمس بسبب مرض المناعة الذاتية (الذئبة الحمامية الجلدية(، الذئبة الحمامية الجهازية، وتفاعلات الحساسية الحادة (تفاعلات تأقية)، وزيادة الحساسية للضوء (الشمس) (الحساسية الضوئية)، وسرطان الجلد والشفاه (سرطان الجلد غير الميلانينيّ).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أُصبت بأي من هذه الآثار الجانبية، فأبلغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول أيدي الأطفال أو مرآهم.</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">فترة الصلاحية: 3 سنوات</p><p dir="RTL">لا تستخدم تيفيتين بلس بعد انتهاء تاريخ الصلاحية المذكور على كل من الشريط والعبوة الخارجية. تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك</p><p dir="RTL">الشهر.</p><p dir="RTL">لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية</p><p dir="RTL">التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة<strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما</strong><strong> </strong><strong>تحويه</strong><strong> </strong><strong>علبة</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس</strong></p><p dir="RTL">المادة الفعالة هي 600 ملغم إبروسارتان (على هيئة ميسيلات) و 12.5 ملغم هيدروكلوروثيازيد لكل قرص.</p><p dir="RTL">المكونات الأخرى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلب القرص: لاكتوز أحادي الهيدرات، سليلوز دقيق التبلور، نشا سابق التجلتن (من الذرة)، كروسبوفيدون وستيرات المغنيسيوم وماء نقي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غلاف القرص: كحول البولي فينيل، تلك، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأسود (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل</strong><strong> </strong><strong>تيفيتين</strong><strong> </strong><strong>بلس</strong><strong> </strong><strong>ومحتويات</strong><strong> </strong><strong>العلبة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تيفيتين بلس، أقراص مغطاة بطبقة رقيقة عبارة عن أقراص على شكل كبسولة، ذات لون حلوى الكرميل بالزبدة محفور عليها</p><p dir="RTL">علامة 5147 على أحد جانبيها. تحتوي العبوة على شرائط بها 7 أو 14 أو 28 أو 56 أو 98 قرصاً.</p><p dir="RTL">عبوات الأشرطة مصنوعة من PVC/PCTFE/Alu معتم الرؤية.</p><p dir="RTL">قد لا تتوفر كافة العبوات في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب</strong><strong> </strong><strong>حق</strong><strong> </strong><strong>التسويق والشركة المصنعة</strong></p><p dir="RTL"><strong>صاحب</strong><strong> </strong><strong>حق</strong><strong> </strong><strong>التسويق</strong></p><p dir="RTL">أبوت لابوراتوريز -جي ام بي اتش</p><p dir="RTL">هانوفر، ألمانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">مايلان لابوراتوريز إس اي إس</p><p dir="RTL">01400 شاتيلون- سور -شالارون، فرنسا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تم</strong><strong> </strong><strong>التغليف</strong><strong> </strong><strong>في</strong><strong>:</strong></p><p dir="RTL">شركة أجا للصناعات الدوائية المحدودة (أجا فارما(</p><p dir="RTL">حائل 55414، المدينة الصناعية، حائل</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت أحدث مراجعة لهذه النشرة بتاريخ نوفمبر 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Teveten® Plus 600 mg/12.5 mg, film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains eprosartan mesylate equivalent to 600 mg eprosartan and 12.5 mg
hydrochlorothiazide.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
Butterscotch-coloured, capsule-shaped film-coated tablets
The inscription of the tablet is 5147 on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Essential hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The recommended dose is one tablet Teveten Plus 600 mg/12.5 mg once daily, which should be taken<br />in the morning. The switch from eprosartan monotherapy to the fixed combination can be considered<br />after 8 weeks of blood pressure stabilization.<br />Elderly<br />No dose adjustment is required in the elderly, although limited information is available in this<br />population.<br />Paediatric population<br />As safety and efficacy of administration to children have not been established, treatment of children<br />and adolescents &lt; 18 years with Teveten Plus 600 mg/12.5 mg is not recommended.</p><p>Hepatic Impairment</p><p>The use of Teveten Plus in patients with mild to moderate hepatic impairment is not recommended<br />since there is currently only limited experience of eprosartan mesylate in this patient group. In patients<br />with severe hepatic impairment Teveten Plus is contraindicated (see section 4.3 and 4.4).</p><p>Renal Impairment<br />In patients with mild to moderate renal impairment (creatinine clearance &ge; 30 ml/min) dose adjustment<br />is not necessary. Teveten Plus is contraindicated in patients with severe renal impairment (see sections<br />4.3 and 4.4).<br />Type of application<br />Teveten Plus 600 mg / 12.5 mg can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to eprosartan, sulfonamide-derived substances (as hydrochlorothiazide) or to any
of the excipients listed in section 6.1 excipients.
• Second and third trimesters of pregnancy (see sections 4.4 and 4.6)
• Severe hepatic impairment
• Cholestasis and biliary obstructive disorders
• Severe renal impairment (creatinine clearance < 30 ml/min)
• Haemodynamically significant bilateral renovascular disease or severe stenosis of a solitary
functioning kidney
• Therapy resistant hypokalaemia or hypercalcaemia
• Refractory hyponatraemia
• Symptomatic hyperuricaemia/gout
• The concomitant use of Teveten Plus 600 mg/12.5 mg with aliskiren-containing products is
contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2)
(see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with a history of allergies<br />including hypersensitivity to sulfonamide-derived substances.</p><p>Patients at risk of renal impairment<br />Some patients whose renal function is dependent on the continued inherent activity of the reninangiotensin-<br />aldosterone system (e.g., patients with severe cardiac insufficiency [NYHA-classification:<br />class IV], bilateral renal artery stenosis, or renal artery stenosis of a solitary kidney), have risks of<br />developing oliguria and/or progressive azotaemia and rarely acute renal failure during therapy with an<br />angiotensin converting enzyme (ACE) inhibitor. These events are more likely to occur in patients<br />treated concomitantly with a diuretic. Angiotensin II receptor (type AT1) blockers such as eprosartan<br />have not had adequate therapeutic experience to determine if there is a similar risk of developing renal<br />function compromise in these susceptible patients. Renal function should be monitored closely,<br />because there is an increased risk for severe hypotension and renal insufficiency in these patients.</p><p>Renal impairment and renal transplant<br />When eprosartan + hydrochlorothiazide is to be used in patients with renal impairment, renal function,<br />serum potassium, and uric acid should be assessed before starting treatment with eprosartan +<br />hydrochlorothiazide and at intervals during the course of therapy. If worsening of renal function is<br />observed during therapy, treatment with eprosartan + hydrochlorothiazide should be reassessed (see&nbsp;section 4.3). Hydrochlorothiazide-associated azotaemia may occur in patients with impaired renal<br />function.<br />There is no experience with Teveten Plus 600 mg/12.5 mg in patients with renal transplants.</p><p>Hepatic Impairment<br />When eprosartan is used in patients with mild to moderate hepatic impairment, special care should be<br />exercised due to the fact that there is limited experience in this patient population.<br />Hydrochlorothiazide should only be used with care in patients with mild to moderate hepatic<br />insufficiency as it may cause intrahepatic cholestasis. Alterations of fluid and electrolyte balance may<br />precipitate hepatic coma.<br />Metabolic and endocrine disturbances<br />Hydrochlorothiazide may impair glucose tolerance and this may require dose adjustment of<br />antidiabetic medication (see section 4.5). Latent diabetes mellitus may become manifest during<br />Teveten Plus 600 mg/12.5 mg treatment. At doses of 12.5 mg hydrochlorothiazide in Teveten Plus 600<br />mg/12.5 mg only mild metabolic and endocrine undesirable effects were observed (increase in serum<br />cholesterol and triglycerides).<br />Electrolyte imbalance<br />Hydrochlorothiazide may cause fluid or electrolyte imbalance (hypokalaemia, hyponatraemia,<br />hypercalcaemia, hypomagnesaemia and hypochloremic alkalosis).<br />As for any patients receiving diuretic therapy, periodic determination of serum electrolytes should be<br />considered. Potassium-sparing diuretics, potassium supplements or potassium-containing salts<br />substitutes should be co-administered cautiously with eprosartan (see section 4.5).</p><p><strong>Choroidal effusion, Acute Myopia and Secondary Angle-Closure Glaucoma</strong></p><p>Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in choroidal effusion with visual field defect, acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p>&nbsp;</p><p>Hypotension<br />Symptomatic hypotension may occur in patients with severe sodium or volume depletion, e.g. as a<br />result of high doses of diuretics, dietary salt restriction, diarrhoea or vomiting. Sodium and/or volume<br />depletion should be corrected before treatment with Teveten Plus 600 mg/12.5 mg.<br />Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy<br />As with other vasodilators patients with aortic or mitral valve stenosis or obstructive hypertrophic<br />cardiomyopathy should be treated with caution.<br />Primary Hyperaldosteronism<br />Patients with primary hyperaldosteronism do not react sufficiently on antihypertensives which act<br />through inhibition of the Renin-Angiotensin-Aldosterone system. Therefore, treatment with Teveten<br />Plus 600 mg/12.5 mg is not recommended.<br />Coronary Heart Disease<br />There is limited experience in patients with coronary heart disease.<br />Pregnancy<br />Angiotensin II receptor blockers should not be initiated during pregnancy. Unless continued<br />angiotensin II receptor blockers therapy is considered essential, patients planning pregnancy should be&nbsp;</p><p>changed to alternative anti-hypertensive treatments which have an established safety profile for use in<br />pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor blockers should be<br />stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and<br />4.6).</p><p>Other warnings and precautions<br />Thiazide diuretics have been reported to exacerbate or activate systemic lupus erythematosus.<br />Hydrochlorothiazide may lead to a positive result in doping tests.<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS)<br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or<br />aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including<br />acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin<br />II receptor blockers or aliskiren is therefore not recommended (see section 4.5 and 5.1).<br />If dual blockade therapy is considered absolutely necessary, this should only occur under specialist<br />supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with<br />diabetic nephropathy.<br />Lactose warning<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose<br />malabsorption should not take this medicinal product.</p><p>Non-melanoma skin cancer<br />An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous<br />cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has<br />been observed in two epidemiological studies based on the Danish National Cancer Registry.<br />Photosensitizing actions of HCTZ could act as a possible mechanism for NMSC. Patients taking<br />HCTZ should be informed of the risk of NMSC and advised to regularly check their skin for any new<br />lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited<br />exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to<br />the patients in order to minimize the risk of skin cancer. Suspicious skin lesions should be promptly<br />examined potentially including histological examinations of biopsies. The use of HCTZ may also need<br />to be reconsidered in patients who have experienced previous NMSC.<br /><br />&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Potential interactions related to both eprosartan and hydrochlorothiazide:<br />Concomitant use not recommended<br />Lithium:<br />Reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with angiotensin converting enzyme inhibitors and, rarely, with<br />angiotensin II receptor (type AT1) blockers. In addition, renal clearance of lithium is reduced by<br />thiazides and consequently the risk of lithium toxicity may be increased. Therefore use of Teveten<br />Plus 600 mg/12.5 mg and lithium in combination is not recommended (see section 4.4). If use of the<br />combination proves necessary, careful monitoring of serum lithium levels is recommended.<br />Concomitant use requiring caution<br />Baclofen:<br />Potentiation of antihypertensive effect may occur.<br />Non-steroidal anti-inflammatory medicinal products:</p><p>As with ACE inhibitors, concomitant use of angiotensin II receptor (type AT1) blockers and NSAIDs<br />may lead to an increased risk of worsening renal function, including possible acute renal failure, and<br />an increase in serum potassium, especially in patients with poor pre-existing renal function. The<br />combination should be administered with caution, especially in the elderly. Patients should be<br />adequately hydrated and consideration should be given to monitoring of renal function after initiation<br />of concomitant therapy and periodically thereafter. Concomitant use of losartan with the NSAID<br />indometacin led to a decrease in efficacy of the angiotensin II receptor blocker, a class effect cannot be<br />excluded.</p><p>Concomitant use to be taken into account<br />Amifostine:<br />Potentiation of antihypertensive effect may occur.<br />Other antihypertensive agents:<br />The blood pressure lowering effect of Teveten Plus 600 mg/12.5 mg can be increased by concomitant<br />use of other antihypertensive medicinal products.<br />Alcohol, barbiturates, narcotics or antidepressants:<br />Potentiation of orthostatic hypotension may occur.</p><p>Potential interactions related to eprosartan:<br />Concomitant use not recommended<br />Medicinal products affecting potassium levels:<br />Based on experience with the use of other medicinal products that affect the renin-angiotensin system,<br />concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing<br />potassium or other medicinal products that may increase serum potassium levels (eg heparin, ACE<br />inhibitors) may lead to increases in serum potassium. If medicinal product which affect potassium<br />levels are to be prescribed in combination with Teveten Plus 600 mg/12.5 mg, monitoring of<br />potassium plasma levels is advised (see section 4.4).<br />Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS)<br />through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated<br />with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal<br />function (including acute renal failure) compared to the use of a single RAAS-acting agent (see<br />sections 4.3, 4.4 and 5.1).</p><p>Potential interactions related to hydrochlorothiazide:<br />Concomitant use not recommended<br />Medicinal products affecting potassium levels:<br />The potassium-depleting effect of hydrochlorothiazide may be potentiated by the coadministration of<br />other medicinal products associated with potassium loss and hypokalaemia (eg other kaliuretic<br />diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium or<br />salicylic acid derivatives). Such concomitant use is therefore not recommended (see section 4.4).<br />Concomitant use requiring caution<br />Calcium salts and Vitamin D:<br />Thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium<br />supplements or medicinal products affecting serum calcium levels (e.g. Vitamin D therapy) must be<br />prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly.<br />Cholestyramine and colestipol resins:<br />Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins such as<br />cholestyramine or colestipol.</p><p>However, the interaction might be minimized by graded intake of hydrochlorothiazide and the resin in<br />the way that hydrochlorothiazide is taken at least 4 hours before or 4-6 hours after the resins.<br />Cardiac glycosides:<br />Thiazide-induced hypokalaemia or hypomagnesaemia may favour the onset of digitalis-induced<br />cardiac arrhythmias.<br />Medicinal products affected by serum potassium disturbances:<br />Periodic monitoring of serum potassium and ECG is recommended when Teveten Plus 600 mg/12.5<br />mg is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis<br />glycosides and antiarrhythmics) and with the following torsades de pointes (ventricular tachycardia)-<br />inducing medicinal products (including some antiarrhythmics), hypokalaemia being a predisposing<br />factor to torsades de pointes (ventricular tachycardia):<br />&bull; Class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide).<br />&bull; Class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide).<br />&bull; Some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine,<br />cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol).<br />&bull; Others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine,<br />terfenadine, vincamine IV).</p><p>Non-depolarizing skeletal muscle relaxants (eg tubocurarine):<br />The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide.<br />Anticholinergic agents (eg atropine, biperiden):<br />Increase of the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and<br />stomach emptying rate.<br />Antidiabetic medicinal products (oral agents and insulin):<br />The treatment with a thiazide may influence the glucose tolerance. Dosage adjustment of the<br />antidiabetic medicinal product may be required (see section 4.4).<br />Metformin:<br />Metformin should be used with caution because of the risk of lactic acidosis induced by possible<br />functional renal failure linked to hydrochlorothiazide.<br />Beta-blockers and diazoxide:<br />The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.<br />Sympathomimetics (eg noradrenaline):<br />The effect of pressor amines may be decreased.</p><p>Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol):<br />Dosage adjustment of uricosuric medicinal products may be necessary since hydrochlorothiazide may<br />raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be<br />necessary. Coadministration of a thiazide may increase the incidence of hypersensitivity reactions to<br />allopurinol.<br />Amantadine:<br />Thiazides may increase the risk of adverse effects caused by amantadine.<br />Cytotoxic agents (eg cyclophosphamide, methotrexate):<br />Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their<br />myelosuppressive effects.<br />Tetracyclines:</p><p>Concomitant administration of tetracyclines and thiazides increases the risk of tetracycline-induced<br />increase in urea. This interaction is probably not applicable to doxycycline.<br />Medicinal products lowering serum sodium level<br />The hyponatraemic effect of hydrochlorothiazide may be intensified by concomitant administration of<br />drugs such as antidepressants, antipsychotics, antiepileptics, etc. Caution is advised in long-term<br />administration of these drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Angiotensin II receptor (type AT1)blocker:<br />The use of angiotensin II receptor blockers is not recommended during the first trimester of pregnancy<br />(see section 4.4). The use of angiotensin II receptor blockers is contraindicated during the second and<br />third trimesters of pregnancy (see sections 4.3 and 4.4).<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors<br />during the first trimester of pregnancy has not been conclusive; however a small increase in risk<br />cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II<br />receptor blockers, similar risks may exist for this class of drugs. Unless continued angiotensin II<br />receptor blocker therapy is considered essential, patients planning pregnancy should be changed to<br />alternative antihypertensive treatments which have an established safety profile for use in pregnancy.<br />When pregnancy is diagnosed, treatment with angiotensin II receptor blockers should be stopped<br />immediately and, if appropriate, alternative therapy should be started.<br />Exposure to angiotensin II receptor blocker therapy during the second and third trimesters is known to<br />induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation)<br />and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (See section 5.3.). Should exposure<br />to angiotensin II receptor blockers have occurred from the second trimester of pregnancy, ultrasound<br />check of renal function and skull is recommended. Infants whose mothers have taken angiotensin II<br />receptor blockers should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>Hydrochlorothiazide<br />There is limited experience with hydrochlorothiazide during pregnancy, especially during the first<br />trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the<br />pharmacological mechanism of action of hydrochlorothiazide its use during the second and third<br />trimesters may compromise the foeto-placental perfusion and may cause foetal and neonatal effects<br />like icterus, disturbance of electrolyte balance and thrombocytopenia. Hydrochlorothiazide should not<br />be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased<br />plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.<br />Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare<br />situations where no other treatment could be used.<br />Breast-feeding<br />Angiotensin II receptor (type AT1) blockers:<br />Because no information is available regarding the use of Teveten Plus 600 mg/12.5 mg during<br />breastfeeding, Teveten Plus 600 mg/12.5 mg is not recommended and alternative treatments with<br />better established safety profiles during breast-feeding are preferable, especially while nursing a<br />newborn or preterm infant.<br />Hydrochlorothiazide:<br />Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing<br />intense diuresis can inhibit the milk production. The use of Teveten Plus 600 mg/12.5 mg during<br />breast feeding is not recommended. If Teveten Plus 600 mg/12.5 mg is used during breast feeding,<br />doses should be kept as low as possible.<br />Fertility<br />There are no clinical data on fertility.<br />Nonclinical data on eprosartan did not reveal any effects on male and female fertility. No preclinical<br />information on possible effects of hydrochlorothiazide on fertility is available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the ability to drive and use machines have been performed, but based on its<br />pharmacodynamic properties, Teveten Plus 600 mg/12.5 mg is unlikely to affect this ability. When<br />driving vehicles or operating machines, it should be taken into account, that occasionally dizziness or<br />weariness may occur during treatment of hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile<br />The most commonly reported adverse drug reactions of patients treated with eprosartan+<br />hydrochlorothiazide are headache and unspecific gastrointestinal complaints occurring in<br />approximately 11% and 8% of patients (versus 14% and 8% with placebo) respectively.<br />b. Summary of adverse reactions<br />Adverse drug reactions (ADRs) that occurred in placebo-controlled clinical trials or reported from the<br />scientific literature are summarized in the Table below. Under each frequency category, ADRs are<br />listed based on data from eprosartan, the combination eprosartan+hydrochlorothiazide, as well as<br />hydrochlorothiazide alone (see table footnotes).</p><p><strong><em>c. Description of selected adverse reactions</em></strong></p><p>Cases of choroidal effusion with visual field defect have been reported after the use of thiazide</p><p>and thiazide-like diuretics. If cases are to be reported for these substances in the future, the appropriate procedure should be used to update the product information accordingly.</p><p>&nbsp;</p><p style="text-align:center">ADVERSE DRUG REACTIONS REPORTED IN PLACEBO CONTROLLED TRIALS AND<br />SCIENTIFIC LITERATURE</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:86px">MedDRA<br />system organ<br />class</td><td style="width:66px">Very<br />common<br />&ge;1/10</td><td style="width:65px">Common<br />&ge;1/100 to<br />&lt;1/10</td><td style="width:72px">Uncommon<br />&ge;1/1,000 to<br />&lt;1/100</td><td style="width:72px">Rare<br />&ge;1/10,000<br />to &lt;1/1,000</td><td style="width:59px">Very rare<br />&lt;1/<br />10,000</td><td style="width:79px">Unknown<br />(cannot be estimated<br />from available data)</td></tr><tr><td style="width:86px">Blood &amp; lymphatic<br />system<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">&nbsp;</td><td style="width:72px">Leukopenia</td><td style="width:72px">&nbsp;</td><td style="width:59px">Haemolytic<br />anaemia*</td><td style="width:79px">Agranulocytosis<br />Aplastic anaemia<br />Thrombocytopenia</td></tr><tr><td style="width:86px">Immune<br />system<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">&nbsp;</td><td style="width:72px">Hypersensitivity</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">Anaphylactic<br />reactions</td></tr><tr><td style="width:86px">Metabolism<br />and<br />nutrition<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">Hyperglycaemia</td><td style="width:72px">Hypokalaemia<br />Hyponatraemia<br />Hypochloraemia<br />Hyperuricaemia<br />Gout<br />Hypercholesterolaemia</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">Hypercalcaemia<br />Hypomagnesaemia<br />Hypertriglyceridaemia<br />Anorexia</td></tr><tr><td style="width:86px">Psychiatric<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">&nbsp;</td><td style="width:72px">Depression<br />Anxiety<br />Insomnia<br />Nervousness<br />Libido disorder</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">Restlessness</td></tr><tr><td style="width:86px">Nervous<br />system<br />disorders</td><td style="width:66px">Headache**</td><td style="width:65px">Dizziness<br />Paraesthesia</td><td style="width:72px">&nbsp;</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">&nbsp;</td></tr><tr><td style="width:86px">Eye disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">&nbsp;</td><td style="width:72px">&nbsp;</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px"><p>Acute myopia and<br />secondary angleclosure<br />glaucoma*</p><p>Choroidal effusion</p></td></tr><tr><td style="width:86px">Ear and labyrinth<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">&nbsp;</td><td style="width:72px">Vertigo**</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">&nbsp;</td></tr><tr><td style="width:86px">Vascular<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">Hypotension<br />(e.g.<br />orthostatic)</td><td style="width:72px">&nbsp;</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">Vasculitis</td></tr><tr><td style="width:86px">Respiratory<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">Rhinitis</td><td style="width:72px">&nbsp;</td><td style="width:72px">Pulmonary<br />oedema*<br />Pneumonitis*</td><td style="width:59px">&nbsp;</td><td style="width:79px">&nbsp;</td></tr><tr><td style="width:86px">Gastrointestinal<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">Unspecific gastrointestinal<br />complaints<br />(e.g. nausea,<br />diarrhoea,<br />vomiting)</td><td style="width:72px">Constipation**</td><td style="width:72px">Pancreatitis*</td><td style="width:59px">&nbsp;</td><td style="width:79px">&nbsp;</td></tr><tr><td style="width:86px">Hepatobiliary<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">&nbsp;</td><td style="width:72px">&nbsp;</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">Jaundice (intrahepatic<br />cholestatic jaundice)</td></tr><tr><td style="width:86px">Skin and subcutaneous<br />tissue<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">Allergic skin<br />reactions<br />(e.g. rash,<br />pruritus)</td><td style="width:72px">Angioedema</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">Toxic epidermal<br />necrolyis<br />Photosensitivity<br />Cutaneous lupus<br />erythematosus</td></tr><tr><td style="width:86px">Musculoskeletal<br />and<br />connective<br />tissue<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">&nbsp;</td><td style="width:72px">Muscle<br />spasms**</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">Systemic lupus<br />erythematosus</td></tr><tr><td style="width:86px">Renal and<br />urinary<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">&nbsp;</td><td style="width:72px">&nbsp;</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">Interstitial nephritis<br />Renal failure/ impaired<br />renal function<br />in patients at risk (e.g.<br />renal artery stenosis)</td></tr><tr><td style="width:86px">Reproductive<br />system/breast<br />disorders</td><td style="width:66px">&nbsp;</td><td style="width:65px">&nbsp;</td><td style="width:72px">Sexual<br />dysfunction</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">&nbsp;</td></tr><tr><td style="width:86px">General disorders<br />and<br />administration<br />site reactions</td><td style="width:66px">&nbsp;</td><td style="width:65px">Asthenia</td><td style="width:72px">Pyrexia</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">&nbsp;</td></tr><tr><td style="width:86px">Neoplasms<br />benign,<br />malignant and<br />unspecified (incl<br />cysts and<br />polyps)</td><td style="width:66px">&nbsp;</td><td style="width:65px">&nbsp;</td><td style="width:72px">&nbsp;</td><td style="width:72px">&nbsp;</td><td style="width:59px">&nbsp;</td><td style="width:79px">Non-melanoma skin<br />cancer (Basal cell<br />carcinoma and<br />Squamous cell<br />carcinoma)***</td></tr></tbody></table><p>* Frequency based on data from the hydrochlorothiazide scientific literature<br />** Did not occur in a higher frequency than in placebo<br />*** Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ<br />and NMSC has been observed (see also sections 4.4 and 5.1).</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It<br />allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions.</p><p><strong>To report any side effect(s):</strong></p><p>-National Pharmacovigilance Center (NPC)</p><p><strong>o </strong>Fax: +966-11-205-7662</p><p><strong>o</strong> SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available in regard to overdose in humans. There have been individual reports from<br />postmarketing experience where doses up to 12,000 mg of eprosartan had been ingested. Although<br />most patients reported no symptoms, it has to be noted however thatin one subject circulatory collapse<br />occurred after ingestion of 12,000 mg eprosartan. The subject recovered completely. For eprosartan +<br />hydrochlorothiazide a maximum ingested dose was 3600 mg eprosartan/75 mg hydrochlorothiazide. It<br />was reported in a case of a suicide attempt.<br />The most likely manifestation of overdose would be hypotension.<br />Other symptoms may be due to dehydration and electrolyte depletion (hypokalaemia, hypochloraemia,<br />hyponatraemia) and will most likely present as nausea and somnolence. Treatment should be<br />symptomatic and supportive. Eprosartan is not removed by haemodialysis. The degree to which<br />hydrochlorothiazide is removed by haemodialysis has not been established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Eprosartan and diuretics, ATC code: C09DA02<br />Eprosartan<br />Eprosartan is a non-peptide, orally active non-biphenyl non-tetrazole angiotensin II receptor (type<br />AT1) blocker, which selectively binds to the AT1-receptor.<br />Angiotensin II plays a major role in the pathophysiology of hypertension. It is the primary active<br />hormone of the Renin-Angiotensin-Aldosterone system and a potent vasoconstrictor.<br />Eprosartan antagonised the effect of angiotensin II on blood pressure, renal blood flow and<br />aldosterone secretion in man. Blood pressure control is maintained over a 24 hour period with no first<br />dose postural hypotension or reflex tachycardia. Discontinuation of treatment with eprosartan does not<br />lead to a rapid rebound increase in blood pressure.<br />Eprosartan does not compromise renal autoregulatory mechanisms. In healthy adult males eprosartan<br />has been shown to increase mean effective renal plasma flow.<br />Eprosartan does not potentiate effects relating to bradykinin (ACE mediated) e.g. cough.</p><p>Hydrochlorothiazide<br />Hydrochlorothiazide is an established thiazide diuretic. Thiazides affect the renal tubular mechanisms<br />of electrolyte re-absorption, increasing excretion of fluid, sodium and chloride. The diuretic action of<br />hydrochlorothiazide reduces plasma volume, increases plasma renin activity, increases aldosterone<br />secretion, with consequential increases in urinary potassium and bicarbonate loss and decreases in</p><p>serum potassium. The antihypertensive action of hydrochlorothiazide appears to be due to combined<br />diuretic and direct vascular activity (reduction of vascular resistance) mechanism.<br />Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative<br />dosedependent association between HCTZ and NMSC has been observed. One study included a<br />population comprised of 71,533 cases of BCC and of 8,629 cases of SCC matched to 1,430,833 and<br />172,462 population controls, respectively. High HCTZ use (&ge;50,000 mg cumulative) was associated<br />with an adjusted OR of 1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC. A<br />clear cumulative dose response relationship was observed for both BCC and SCC. Another study<br />showed a possible association between lip cancer (SCC) and exposure to HCTZ: 633 cases of lipcancer<br />were matched with 63,067 population controls, using a risk-set sampling strategy. A<br />cumulative doseresponse relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6)<br />increasing to OR 3.9 (3.0-4.9) for high use (~25,000 mg) and OR 7.7 (5.7-10.5) for the highest<br />cumulative dose (~100,000 mg) (see also section 4.4).</p><p>Teveten Plus 600 mg/12.5 mg<br />In a placebo-controlled, 8 weeks clinical trial in 473 patients with essential hypertension it was shown<br />that the combination of 600 mg eprosartan and 12.5 mg hydrochlorothiazide is well tolerated and<br />efficacious. Teveten Plus 600 mg/12.5 mg reduced systolic and diastolic blood pressure to a clinically<br />relevant degree and was statistically significant superior to both individual components and placebo,<br />despite a high placebo response (p=0.08 for comparison of eprosartan alone and placebo). Tolerability<br />was equal for both eprosartan/hydrochlorothiazide 600 mg/12.5 mg, eprosartan and placebo.<br />In another clinical trial patients with a diastolic blood pressure between 98 and 114 mmHg, who were<br />not treated sufficiently with a 3-weeks treatment of eprosartan 600 mg alone, were given either<br />eprosartan/hydrochlorothiazde 600 mg/12.5 mg or 600 mg eprosartan alone for 8 weeks. The<br />combination caused a statistically significant and clinically relevant additional decrease in systolic and<br />diastolic blood pressure in patients not reacting sufficiently to eprosartan monotherapy. Tolerability<br />was equally satisfactory for both the combination and monotherapy.<br />Only limited data is available in patients over 80 years of age.</p><p>The effect of the combination of eprosartan and hydrochlorothiazide on morbidity and mortality was<br />not investigated. Epidemiological studies showed that long term treatment with hydrochlorothiazide<br />reduces the risk for cardiovascular mortality and morbidity.<br />Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in<br />combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs<br />Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an<br />angiotensin II receptor blocker.<br />ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular<br />disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHROND<br />was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and<br />mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as<br />compared to monotherapy was observed. Given their similar pharmacodynamic properties, these<br />results are also relevant for other ACE- inhibitors and angiotensin II receptor blockers.<br />ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in<br />patients with diabetic nephropathy.<br />ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints)<br />was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor<br />or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney<br />disease, cardiovascular disease, or both. The study was terminated early because of an increased risk<br />of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the<br />aliskiren group than in the placebo group and adverse events and serious adverse events of interest</p><p>(hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren<br />group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Eprosartan<br />Absolute bioavailability following oral administration of eprosartan is approx. 13%. Eprosartan<br />plasma concentrations peak at 1 to 2 hours after dosing in the fasted state. The terminal elimination<br />half-life of eprosartan is typically 5 to 9 hours. A slight accumulation (14 %) is seen with chronic use<br />of eprosartan. Administration of eprosartan with food delays absorption, but does not decrease the<br />bioavailability.<br />In the dose range between 100 to 800 mg there is a slight less than dose-proportional increase in<br />exposure to eprosartan, most likely due to the physicochemical properties of the drug.<br />Plasma protein binding of eprosartan is 98% and is not influenced by gender, age, hepatic dysfunction<br />or mild-to moderate renal impairment. Plasma protein binding is decreased in a small number of<br />patients with severe renal impairment.<br />The volume of distribution of eprosartan is approx. 13 litres. Total plasma clearance is approx. 130<br />ml/min. After oral administration of [14C] eprosartan approximately 90% of radioactivity was<br />recovered from faeces. Approximately 7% was excreted in urine, 80% of which as eprosartan. Both<br />AUC and Cmax values for eprosartan are higher in the elderly (on average twofold), but dose<br />adjustment is not necessary. AUC values (but not Cmax) for eprosartan are increased on average by<br />40% in patients with hepatic impairment, but this does not necessitate dose adjustment.<br />Compared to subjects with normal renal function mean AUC and Cmax values were approximately 30%<br />higher in patients with moderate renal impairment (creatinine clearance 30-59 ml/min), approximately<br />50% higher in patients with severe renal impairment (creatinine clearance 5-29 ml/min). There is no<br />difference in the pharmacokinetics between males and females.</p><p>It was shown in vitro that eprosartan does not inhibit human Cytochrome P450 isoenzymes CYP1A,<br />2A6, 2C9/8, 2C19, 2D6, 2E and 3A.<br />Hydrochlorothiazide<br />After oral administration absorption of hydrochlorothiazide is relatively rapid. When given in fasted<br />state the mean elimination half-life is 5-15 hours. Hydrohlorothiazide is not metabolized and is rapidly<br />excreted by the kidneys. At least 61% of an oral dose is excreted unchanged within 24 hours.<br />Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast<br />milk.<br />Teveten Plus 600 mg/12.5 mg<br />Co-administration of eprosartan and hydrochlorothiazide has no clinical significant effect on the<br />pharmacokinetics of either active substance. The bioavailability of eprosartan and hydrochlorothiazide<br />is not influenced by food, but absorption is delayed. Peak plasma concentrations are reached after 4<br />hours for eprosartan and after 3 hours for hydrochlorothiazide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The potential toxicity of the combination eprosartan/hydrochlorothiazide after oral administration was<br />investigated in mice and dogs in studies lasting up to 3 months. No findings emerged that would<br />exclude the use of therapeutic doses in man.<br />The toxicologic target organ was the kidney. The combination eprosartan/hydrochlorothiazide induced<br />functional renal changes (increases in serum urea and in serum creatinine). Furthermore, tubular deand<br />regeneration in the kidneys were induced at higher doses in mice and dogs, probably by way of&nbsp;</p><p>altered renal haemodynamics (reduced renal perfusion as a consequence of hypotension leading to<br />tubular hypoxia with tubular cellular degeneration).<br />Furthermore, the combination induced juxtaglomerular cell hyperplasia, decreases in red blood cell<br />parameters and a decrease in heart weight. These effects appear to be due to the pharmacological<br />effects of high doses eprosartan and also occur with ACE-inhibitors. The relevance of these findings to<br />the use of therapeutic doses of the combination eprosartan/hydrochlorothiazide in humans is unknown.<br />Findings from in vitro and in vivo studies with eprosartan and hydrochlorothiazide both alone and in<br />combination did not reveal a relevant genotoxic potential.<br />Carcinogenicity studies were not performed with the combination eprosartan/hydrochlorothiazide.<br />Carcinogenicity was not observed in rats and mice, administered eprosartan up to 600 mg or 2000<br />mg/kg daily respectively for 2 years. The extensive human experience with hydrochlorothiazide has<br />failed to show an association between its use and an increase in neoplasms.<br />In pregnant rabbits, eprosartan has been shown to produce maternal and fetal mortality at 10 mg/kg<br />per day during late pregnancy only. Hydrochlorothiazide did not enhance maternal and embryo-fetal<br />toxicity of eprosartan. The combination eprosartan/hydrochlorothiazide administered orally at doses<br />up to 3/1 mg/kg/day (eprosartan/hydrochlorothiazide) resulted in neither maternal nor fetal<br />developmentally toxic effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:<br />Lactose monohydrate<br />Microcrystalline cellulose<br />Pregelatinised starch (from maize)<br />Crospovidone (type B according to Ph. Eur.)<br />Magnesium stearate (Ph. Eur.) [Vegetable]<br />Purified water</p><p>Film coat:<br />Polyvinyl alcohol<br />Talc<br />Titanium dioxide (E171)<br />Macrogol 3350<br />Iron oxide yellow (E172)<br />Iron oxide black (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>White PVC/PCTFE/Aluminium foil blisters</p><p>Original packs of :<br />7 film-coated tablets<br />14 film-coated tablets<br />28 film-coated tablets<br />56 film-coated tablets<br />98 film-coated tablets<br />Hospital pack with:<br />280 (10 x 28) film-coated tablets<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott laboratories GmbH
Hannover, Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2020 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>